elacestrant significantly prolongs pfs for er /her2- metastatic bc without prior chemotherapy pts
Published 2 years ago • 747 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
3:24
elacestrant shows improved pfs in patients with er-positive/her2-negative metastatic breast cancer
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
7:26
sacituzumab govitecan increases pfs for hr /her2‐ advanced breast cancer patients
-
3:59
sacituzumab govitecan increases pfs for hr /her2- metastatic breast cancer
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
4:39
serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
-
25:14
metastatic her2 negative breast cancer: emerging novel treatment strategies
-
0:57
enhertu - what it is and how it works #breastcancer
-
2:15
treat ctdna: early elacestrant intervention for er /her2- breast cancer
-
8:52
hr–positive advanced breast cancer: ribociclib improved pfs for pre and perimenopausal women
-
7:08
selective oestrogen receptor degraders as treatment for er positive/her2 negative advanced/metas...
-
31:21
novel therapeutics for breast cancer: her2 and triple negative disease; new pathways, targets
-
44:23
metastatic breast cancer: leveraging clinical pathways to navigate a complex treatment landscape:
-
4:01
management of her2 positive metastatic breast cancer treatment algorithm
-
59:29
first-line endocrine-based therapy for patients with hr , her2-negative metastatic breast cancer
-
0:43
understanding the benefits and risks of chemotherapy for breast cancer patients 🎗️💊
-
0:30
stages of breast cancer
-
4:34
lasofoxifene vs fulvestrant for locally advanced/metastatic er /her2- breast cancer: elaine trial